← All drugs Report issue

pr1 peptide

Vaccineexperimental

Clinical trial activity

7 trials · 6 clinical orgs · 0 marketing orgs

Phase 1

3

Phase 2

5

Phase 3

1

Phase 4

0

Earliest trial started Dec 1, 1999 (NCT00004918)

Timeline

1990s

Jan 1, 1999
Earliest Phase 1 Sponsor(trial)

2000s

Jan 1, 2005
Earliest Phase 3 Sponsor(trial)
Jan 1, 2006
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Leukemia cellsImmunity, active
immunity, active - leukemia cells

Chemistry & pharmacology

Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

NCATS54XUF2TZ7G ↗
ChEMBLCHEMBL4297811 ↗

Also known as

peptide vaccine (pr1 peptide)
pr1 leukemia peptide vaccine
wt1 and pr1 peptide

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02873767	Phase 1	Aug 1, 2016	Hoosier Cancer Research Network
NCT00488592	Phase 2	Jun 1, 2007	National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
NCT00513578	Phase 2	Jan 1, 2007	The Vaccine Company
NCT00415857	Phase 2	Dec 1, 2006	The Vaccine Company, University of Texas at Houston
NCT00270452	Phase 1	Dec 22, 2005	National Heart, Lung, and Blood Institute (NHLBI)
NCT00454168	Phase 3	May 1, 2005	The Vaccine Company
NCT00004918	Phase 1/Phase 2 (Phase 2)	Dec 1, 1999	National Cancer Institute (NCI), University of Texas at Houston

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (6)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
The Vaccine Company	For profit	3	2	2	2005
National Heart, Lung, and Blood Institute (NHLBI)	Government	2	2	2	2005
University of Texas at Houston	Academic/Hospital	2	1	1	1999
Hoosier Cancer Research Network	Academic/Hospital	1	1	1	2016
National Cancer Institute (NCI)	Government	1	1	1	1999
National Institutes of Health (NIH)	Government	1	0	1	2007

6 organizations

Page 1 / 1